Browsing Tag
GIST
2 posts
Could three FDA submissions turn bezuclastinib into a rare disease and oncology launch engine?
Cogent’s AdvSM NDA gives COGT a third bezuclastinib FDA submission, sharpening its KIT-driven disease franchise and late-2026 launch story.
Hoth Therapeutics advances HT-KIT: Preclinical success sets stage for human trials and stock market interest
Hoth Therapeutics reports tumor suppression with no toxicity for HT-KIT. Learn how this biotech play could reshape cancer care and investor sentiment.